Images List Premium Download Classic

Neoplasm

Neoplasm-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Benzimidazol-2-amines as midh1 inhibitors
Bayer Pharma Aktiengesellschaft
November 09, 2017 - N°20170320861

The present invention relates to benzim-idazol-2-amines of general formula (i) in which r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 and r12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for ...
1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
Bayer Pharma Aktiengesellschaft
November 09, 2017 - N°20170319549

The present invention relates to benzimidazol-2-amines of general formula (i) in which r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 and r12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for ...
Substituted tetracycline compounds
Paratek Pharmaceuticals, Inc.
October 26, 2017 - N°20170305840

The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
Neoplasm Patent Pack
Download + patent application PDFs
Neoplasm Patent Applications
Download + Neoplasm-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Neoplasm-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combinations for the treatment of neoplasms using quiescent cell targeting with egfr inhibitors
Paratek Pharmaceuticals, Inc.
October 19, 2017 - N°20170296541

The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with egfr inhibitor agents.
Detection method
Commonwealth Scientific And Industrial Research Organisation
September 14, 2017 - N°20170260585

The present invention relates generally to an array of nucleic acid molecules, the expression profiles of which characterise the anatomical origin of a cell or population of cells within the large intestine. More particularly, the present invention relates to an array of nucleic acid molecules, the expression profiles of which characterise the proximal or distal origin of a cell or ...
Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
Pharosgen
September 14, 2017 - N°20170260278

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (pah), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
Neoplasm Patent Pack
Download + patent application PDFs
Neoplasm Patent Applications
Download + Neoplasm-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Neoplasm-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for treating b-lymphoid malignancies
The Trustees Of The University Of Pennsylvania
August 24, 2017 - N°20170239294

Compositions and methods for inhibiting, treating, and/or preventing a b-cell neoplasm are provided.
Image analysis method supporting illness development prediction for a neoplasm in a human or animal ...
Stichting Maastricht Radiation Oncology
August 17, 2017 - N°20170236283

The present invention relates to an image analysis method for providing information for supporting illness development prediction regarding a neoplasm in a human or animal body. The method includes receiving for the neoplasm first and second image data at a first and second moment in time, and deriving for a plurality of image features a first and a second image ...
Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments
Chemotherapeutics, Llc
August 17, 2017 - N°20170232037

Methods for treating cancers, tumors, and neoplasms using a composition comprising one or more generally regarded as safe (gras) compounds selected from the group of components consisting of vitamins, selenium, fatty acids, fatty acid salts, and fatty acid esters, and mixtures of two or more said components, either as a stand-alone treatment or in combination with one or more anti-cancer ...
Antineoplastic combinations containing hki-272 and vinorelbine
Wyeth Llc
August 17, 2017 - N°20170231972

A combination of hki-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and method for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
Amino-substituted isoxazoles
Bayer Pharma Aktiengesellschaft
August 03, 2017 - N°20170217946

The present invention relates to amino-substituted isoxazoles of general formula (i): in which a, r1 and r2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment ...
Method of diagnosing neoplasms
Commonwealth Scientific And Industrial Research Organisation
July 27, 2017 - N°20170211152

The present invention relates generally to nucleic acid molecules, the rna and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine ...
Methods for providing personalized medicine test ex vivo for hematological neoplasms
Vivia Biotech, S.l.
July 20, 2017 - N°20170205395

Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the ...
Neoplasm Patent Pack
Download + patent application PDFs
Neoplasm Patent Applications
Download + Neoplasm-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Neoplasm-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Benzimidazol-2-amines as midh1 inhibitors
Bayer Pharma Aktiengesellschaft
July 13, 2017 - N°20170197922

The present invention relates to benzimidazol-2-amines of general formula (i): in which r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 and r12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for ...
Benzimidazol-2-amines as midh1 inhibitors
Bayer Pharma Aktiengesellschaft
July 13, 2017 - N°20170197921

The present invention relates to benzimidazol-2-amines of general formula (i), in which r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 and r12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for ...
Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using ...
New York University School Of Medicine
July 13, 2017 - N°20170196494

The present invention relates to devices and methods of use thereof for detection of biomolecules, in vitro, in vivo, or in situ. The invention relates to methods of diagnosing and/or treating a subject as having or being at risk of developing a disease or condition that is associated with abnormal levels of one or more biomolecules including, but not ...
Methylated markers for colorectal cancer
Clinical Genomics Pty Ltd
July 06, 2017 - N°20170191135

Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
Pharsogen
June 29, 2017 - N°20170183416

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (pah), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
Inhibitors of cyclin-dependent kinase 7 (cdk7)
Syros Pharmaceuticals, Inc.
June 29, 2017 - N°20170183355

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e. G., cancers (e. G., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and ...
Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and ...
Limited Liability Company "russian Pharmaceutical Technologies"
June 29, 2017 - N°20170183315

The present technology relates to medicine and includes the use of inhibitors which selectively interfere with the interaction between a fibroblast growth factor receptor and frs2, and with the interaction with other components of the frs2 complex. Use of the selective inhibitors described in the present technology leads to a proven increase in anti-tumor efficacy relative to other inhibitors and ...
Inhibitors of cyclin-dependent kinase 7 (cdk7)
Syros Pharmaceuticals, Inc.
June 22, 2017 - N°20170174692

The present invention provides novel compounds described herein, such as of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e. G., cancers (e. G., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, ...
Loading